This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Answering the question post #29 raises rather than the one it answers.
Two questions I would want answered before drawing anything from the obstructive sleep apnoea data above: how were the cases selected, and what happened to the ones that dropped out.
Careful with the language on obstructive sleep apnoea. "Not detected" and "not present" are different findings and the first is a statement about the method.
Everything in post #33 holds. The case it does not cover is the one I have.
Comorbidity control: if a comorbidity (high blood pressure, high lipids) is not adequately controlled, the decision about adding compounds in this class depends on the current control status, not on the compound alone.
Happy to expand any of that if it is the useful part.
Narrowing post #33, because the general version has more than one answer.
What I want from this obstructive sleep apnoea thread is the list of things that would need to be true for the claim to hold. If we can write that list, we can check it.
Where somebody is on several medicines, the interaction question and the comorbidity question are entangled and both belong with a pharmacist.
That is my reading. Someone else read the same page differently and was reasonable.
An honest declaration on obstructive sleep apnoea: I have a prior here and it is strong enough that you should weight what I say downward. Stating it rather than hiding it.
Picking up post #38: that is the part I would want checked first.
Gastrointestinal conditions interact with a mechanism that slows gastric emptying in ways that are plausible and largely unstudied.
It is worth stating the boring hypothesis before the interesting one.
Adding the measurement that post #38 says would settle it.
A note on how obstructive sleep apnoea gets discussed rather than on obstructive sleep apnoea itself: the confident posts get the replies and the careful ones get ignored, and the careful ones have been right more often.
A condition that affects nutrition or absorption changes the calculus around a treatment that reduces intake, and that interaction is mostly unstudied.
Nothing above should be read as advice about what anyone else should do.
Nothing here is medical advice and clinicians posting in this subcategory say so on their own account rather than because a rule requires it.
The disagreement above is smaller than it looks once the terms are fixed.
Where the obstructive sleep apnoea discussion usually stalls is that nobody wants to say "I do not know" and everyone is willing to say "it varies". Those are the same sentence with different clothes on.
No disagreement from me. Posting only so the question does not look ignored.
Chronic kidney disease: compounds in this class have renal benefit in people with kidney disease. The benefit appears to be additive to other renal-protective agents, not a replacement for them.
Coming back to post #44, because the follow-up matters more than the original answer.
The bit of obstructive sleep apnoea that nobody enjoys is that the answer changes depending on what you are trying to decide with it. Say what the decision is and the thread will converge.
PCOS and metabolic overlap: polycystic ovary syndrome has metabolic overlap with obesity and insulin resistance. Data on compounds in this class in PCOS specifically is thin; most discussion is by mechanism.
The part I am sure of is shorter than the part I have written.
This follows post #51 rather than contradicting it.
The question underneath obstructive sleep apnoea is usually "how would I tell?" rather than "what is true?", and that one has a method attached to it.
Write down what you would expect to see under each hypothesis before you collect anything. If they predict the same observation, collecting it will not help.
Understood. Thank you for being specific about the limits of it.
Where a condition is well controlled and where it is not are different questions and the published data rarely distinguishes them.
Adding the caveat now so it does not have to be extracted later.
Taking post #55 at face value and following it one step further.
Nobody has said the unglamorous part of obstructive sleep apnoea yet, so: most of the variation is explained by things that are boring to write about and easy to check.
I read post #55 twice before replying, because I had assumed the opposite.
Answering the obstructive sleep apnoea question as asked, then the question I think is meant. As asked: yes, with the qualification below. As meant: it depends on how the first measurement was taken.
Where the honest answer is "nobody knows", giving it plainly is more useful than a confident synthesis of mechanism and anecdote.
PCOS and metabolic overlap: polycystic ovary syndrome has metabolic overlap with obesity and insulin resistance. Data on compounds in this class in PCOS specifically is thin; most discussion is by mechanism.
The variance between people here is larger than the effect being discussed.